UMCKALOABO

OTHER NAME(S):

African Geranium, EPs 7630, Geranien, Geranio Sudafricano, Geranium, Géranium d’Afrique, Géranium d'Afrique du Sud, Géranium du Cap, Geranium Root, Ikhubalo, Icwayiba, i-Yeza lezikali, Kalwerbossi, Khoaara e Nyenyane, Pelargonien, Pelargonio Sudafricano, Pelargonium Root, Pélargonium d’Afrique, Pélargonium du Cap, Pelargonium sidoides, Rabas, Rabassam, Racine de Géranium, Racine de Pélargonium, South African Geranium, Uvendle.<br/><br/>

Overview

Overview Information

Umckaloabo is a flowering plant that is native to South Africa. Its roots are used for medicine.

Umckaloabo was first promoted in Britain in 1897 as a treatment for tuberculosis. It was marketed by Charles Henry Stevens and was known as “Stevens’ Cure.” It fell out of favor when antibiotics were developed in the mid-1900s.

Umckaloabo is commonly used by mouth for upper respiratory infections including bronchitis, sinusitis, sore throat, tonsillitis, and the common cold. There is limited scientific research to support other uses of Umckaloabo.

How does it work?

Umckaloabo is usually used for infections such as bronchitis and sinus infection. Researchers think that it might work by killing bacteria or preventing bacteria from attaching to surfaces within the body. Umckaloabo might also increase the body's normal response to infection.

Uses

Uses & Effectiveness?

Likely Effective for

  • Bronchitis. Adults and children with bronchitis who start taking a specific Umckaloabo extract within 48 hours of feeling sick seem to have fewer symptoms after 7 days of treatment. Some studies have also used tablet forms of this product. However, the tablets seemed to work only for adults, not children.

Possibly Effective for

  • Common Cold. Taking Umckaloabo extract three times per day seems to help reduce symptoms and clear up the common cold after 10 days of treatment. In asthmatic children with a cold, Umckaloabo liquid improves cough and nasal symptoms.
  • Sore throat and swollen tonsils (tonsillopharyngitis). When given to children experiencing sore throat and swollen tonsils, Umckaloabo extract seems to significantly reduce pain and difficulty swallowing after 4 days of treatment.

Insufficient Evidence for

  • Asthma. Early research suggests that taking Umckaloabo liquid three times daily for 5 days reduces asthma attacks compared to no treatment in children with mild asthma and a cold.
  • Infection in the nose (sinusitis). Early research suggests that taking Umckaloabo extract three times per day helps reduce symptoms and clear up sinusitis after 21 days of treatment.
  • Tuberculosis.
  • Diarrhea.
  • Other conditions.
More evidence is needed to rate Umckaloabo for these uses.

Side Effects

Side Effects & Safety

Umckaloabo extract is LIKELY SAFE when taken by mouth for up to 3 weeks. There is not enough information to know if it is safe when taken for longer periods of time. Some people who take it can experience stomach upset. Some people have had allergic reactions to Umckaloabo.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking Umckaloabo if you are pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: Umckaloabo is POSSIBLY SAFE when taken by mouth for up to one week. There is not enough information to know if it is safe when taken for longer periods of time.

“Auto-immune diseases” such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: Umckaloabo might cause the immune system to become more active. This could increase the symptoms of auto-immune diseases. If you have one of these conditions, it’s best to avoid using Umckaloabo.

Bleeding disorders: A chemical in Umckaloabo, called coumarin, might slow blood clotting and increase bleeding. In theory, Umckaloabo might make bleeding disorders worse.

Surgery: A chemical in Umckaloabo, called coumarin, might slow blood clotting. In theory, Umckaloabo might increase the risk for bleeding during surgical procedures. Stop using Umckaloabo at least 2 weeks before a scheduled surgery.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Medications that decrease the immune system (Immunosuppressants) interacts with UMCKALOABO

    South African geranium might increase the immune system. Taking South African geranium along with some medications that decrease the immune system might decrease the effectiveness of medications that decrease the immune system.<br /><br /> Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others

Dosing

Dosing

The following doses have been studied in scientific research:

ADULTS

BY MOUTH:

  • For bronchitis: 30 drops of a specific extract of Umckaloabo three times daily for 7 days. This same extract in tablet form, 10-30 mg three times daily for 7 days, has also been used.
  • For common cold: 30 drops three times daily of a specific extract of Umckaloabo for 10 days.
CHILDREN

BY MOUTH:
  • For bronchitis: In children age 7-12 years, 20 drops of a specific Umckaloabo extract three times daily for 7 days. In children age 6 years or less, 10 drops of this extract three times daily for 7 days.
  • For common cold: 5-10 drops of a specific extract of Umckaloabo three times daily for 5 days.
  • For sore throat and swollen tonsils in children 6-10 years: 20 drops of a specific extract of Umckaloabo three times daily for 7 days.

View References

REFERENCES:

  • Beil, W. and Kilian, P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine 2007;14 Suppl 6:5-8. View abstract.
  • Chuchalin, A. G., Berman, B., and Lehmacher, W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial. Explore.(NY) 2005;1(6):437-445. View abstract.
  • de Boer, H. J., Hagemann, U., Bate, J., and Meyboom, R. H. Allergic reactions to medicines derived from Pelargonium species. Drug Saf 2007;30(8):677-680. View abstract.
  • Lizogub, V. G., Riley, D. S., and Heger, M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore.(NY) 2007;3(6):573-584. View abstract.
  • Matthys, H. and Heger, M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr.Med Res Opin. 2007;23(2):323-331. View abstract.
  • Matthys, H., Eisebitt, R., Seith, B., and Heger, M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 2003;10 Suppl 4:7-17. View abstract.
  • Schulz, V. Liquid herbal drug preparation from the root of Pelargonium sidoides is effective against acute bronchitis: results of a double-blind study with 124 patients. Phytomedicine 2007;14 Suppl 6:74-75. View abstract.
  • Wittschier, N., Lengsfeld, C., Vorthems, S., Stratmann, U., Ernst, J. F., Verspohl, E. J., and Hensel, A. Large molecules as anti-adhesive compounds against pathogens. J Pharm Pharmacol. 2007;59(6):777-786. View abstract.
  • Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis. A systematic review and meta-analysis. Phytomedicine 2008;15:378-85. View abstract.
  • Bereznoy VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med 2003;9:68-79. View abstract.
  • Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol 2008;119:420-33. View abstract.
  • Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): A randomized, double-blind, placebo-controlled trial. Explore 2005;1:437-45.
  • Conrad A, Hansmann C, Engels I, et al. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. Phytomedicine 2007;14 Suppl 6:46-51. View abstract.
  • Conrad A, Jung I, Tioua D, et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. Phytomedicine 2007;14 Suppl 6:52-9. View abstract.
  • Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother Res 2001;15:122-6. View abstract.
  • Kayser O, Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med 1997;63:508-10. View abstract.
  • Koch E, Biber A. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. Phytomedicine 2007;14 Suppl 6:40-5. View abstract.
  • Kolodziej H, Kayser O, Radtke OA, et al. Pharmacological profile of extracts of Pelargonium sidoides and their constituents. Phytomedicine 2003;10 Suppl 4:18-24. View abstract.
  • Kolodziej H, Kiderlen AF. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine 2007;14 Suppl 6:18-26. View abstract.
  • Matthys H, Heger M. EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine 2007;14 Suppl 6:65-8. View abstract.
  • Matthys H, Kamin W, Funk P, Heger M. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine 2007;14 Suppl 6:69-73. View abstract.
  • Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin 2010;26:1413-22. View abstract.
  • Schnitzler P, Schneider S, Stintzing FC, et al. Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus. Phytomedicine 2008;15:1108-16. View abstract.
  • Schotz K, Noldner M. Mass spectroscopic characterisation of oligomeric proanthocyanidins derived from an extract of Pelargonium sidoides roots (EPs 7630) and pharmacological screening in CNS models. Phytomedicine 2007;14 Suppl 6:32-9. View abstract.
  • Seidel V, Taylor PW. In vitro activity of extracts and constituents of Pelagonium against rapidly growing mycobacteria. Int J Antimicrob Agents 2004;23:613-9. View abstract.
  • Tahan F, Yaman M. Can the Pelargonium sidoides root extract EPs 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children? Phytomedicine 2013;20(2):148-50. View abstract.
  • Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012;63(1):1-9. View abstract.
  • Teschke R, Frenzel C, Wolff A, et al. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement. Ann Hepatol 2012;11(4):500-12. View abstract.
  • Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013;(10):CD006323. View abstract.
  • Timmer A, Günther J, Rücker G, et al. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev 2008;(3):CD006323. View abstract.
  • Wittschier N, Faller G, Hensel A. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach. Phytomedicine 2007;14:285-8. View abstract.

Vitamins Survey

Have you ever purchased UMCKALOABO?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

More Resources for UMCKALOABO

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.